STAT+: Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform

Plenty of pharma execs have decried Democrats’ new drug pricing law. But few are willing to say they might delay treatments for cancer patients if it means making more money.
Click here to view original post